Emerson post-90s Secretary of the Board Xie Minghao also serves as CFO: Medical analyst background, previously worked at Guotai Junan

Ruicai Finance Wu Wenting April 7, Wuhan Aimesen Life Technology Co., Ltd. (hereinafter referred to as “Aimesen”) submitted its prospectus to the Hong Kong Stock Exchange, with CICC and CCB International as joint sponsors.

This is Aimesen’s second attempt to list on the Hong Kong Stock Exchange, having first submitted an application on September 28, 2025.

Aimesen was established in January 2015 and is an early-stage cancer detection company, focusing on high-incidence and high-mortality cancers. The company was the first to develop methylation-based early cancer detection technology.

According to the prospectus, revenue for 2024-2025 was 7.24M yuan and 15.42M yuan, respectively; the total net loss attributable to owners and comprehensive loss for the year was 38.63 million yuan and 48.98M yuan. Notably, its revenue grew by 113.03% year-over-year in 2025.

Currently, the company’s board of directors consists of nine members, including eight executive directors, one non-executive director, and three independent non-executive directors.

Among them, Dr. Zhang Lianglu, 38, is the founder, chairman, executive director, and general manager of the company. He was appointed as a director and general manager on January 28, 2015, and was promoted to executive director on September 20, 2025. As the company’s founder, Zhang Lianglu established the strategic focus on “early cancer detection” and laid the overall business direction. He assembled the core team and technical platform of the company and also founded the bioinformatics team responsible for developing the iTBFinder platform.

Zhang Lianglu holds multiple positions in the medical field, including serving as a standing member of the Tumor Molecular Diagnostics Expert Committee of the Chinese Society of Integrative Medicine from April 2019 to April 2022, a member of the Gastric Cancer Marker Collaboration Group of the Tumor Markers Professional Committee of the Chinese Anti-Cancer Association from June 2019 to June 2020, a director of the Hubei Province Medical Devices and Medical Equipment Clinical Evaluation Society from July 2021 to July 2024, and vice chairman of the Hubei Immunology Society Science Popularization and Education Committee from July 2021 to July 2024. Since January 2025, he has also served as a young member of the Cancer Screening and Early Diagnosis Professional Committee of the Chinese Preventive Medicine Association.

Zhang Lianglu holds a senior engineer professional title in the medical device field, obtained a qualification certificate issued by the Hubei Provincial Department of Human Resources and Social Security in December 2019. He has received multiple honors, including being named a “Young Talent of Hubei Province” in September 2017, a “Yangtze River Scholar of Hubei” in July 2020, and a “Guanggu Entrepreneur Talent” by the Wuhan East Lake High-tech Development Zone Management Committee in October 2016. To recognize his contributions, he received the following awards: the Excellent Award in the In Vitro Diagnostic Group at the Beijing Semi-final of the China Medical Device Innovation and Entrepreneurship Competition in August 2019, the Gold Medal at the 5th China “Internet” College Student Innovation and Entrepreneurship Competition in October 2019, the second prize in the preliminary round and third prize in the final of the IVD Product Startup Group at the China Medical Device Innovation and Entrepreneurship Competition in September 2020, and the First Prize of the Invention Entrepreneurship Achievement Award from the China Invention Association in October 2022.

Outside the medical field, Zhang Lianglu also holds positions in various organizations, including serving as an executive director of the Hubei Youth Entrepreneurs Association since 2022, vice president of the Hubei Shandong Chamber of Commerce since September 2024, executive director of the Hubei Chu Business United Association since May 2022, executive vice president of the Wuhan University Economics and Management Branch since July 2022, director of the Wuhan University Alumni Entrepreneurs Association since March 2023, and president of the Central China Branch of the Shell Society Alumni since June 2023.

Zhang Lianglu obtained a bachelor’s degree in biological engineering from Wuhan University in September 2010 and a master’s degree in pathology and pathophysiology in June 2013. He further earned a Ph.D. in Cell Biology from the School of Life Sciences at Wuhan University in June 2022.

Xie Minghao ( also known as Xie Kun ), 35, joined the group on April 10, 2025, serving as the group’s board secretary from the date of joining, chief financial officer from July 31, 2025, and co-secretary of the group from September 4, 2025. He is mainly responsible for financial planning, capital operations, and investor relations.

Xie Minghao has accumulated relevant experience in healthcare investment. From July 2016 to March 2017, he worked as a healthcare industry analyst in the investment department of CITIC Guoan Tibet Innovation Fund Management Co., Ltd., a company mainly engaged in managing healthcare innovation funds, responsible for evaluating potential investment projects. From April 2017 to May 2021, he served as senior analyst in the healthcare and medical investment departments at Guotai Junan Innovation Investment Co., Ltd., the parent company listed on the Hong Kong Stock Exchange (2611.HK) and the Shanghai Stock Exchange (601211.SH), responsible for private equity investments in healthcare. From May 2021 to August 2022, he was a senior investment manager in the financial development department at Zhengda Tiansheng Pharmaceutical Group Co., Ltd., the parent company listed on the Hong Kong Stock Exchange (1177.HK), responsible for evaluating investment and divestment opportunities and providing related investment advice.

From August 2022 to February 2025, Xie Minghao served as the board secretary of Jiangsu Kexi Biotechnology Co., Ltd., listed on the New Third Board, stock code: 835272. He also obtained securities practitioner qualification certificates in September 2011 and July 2015, and fund practitioner and board secretary qualification certificates issued by the Shenzhen Stock Exchange in November 2016 and December 2024, respectively.

In June 2013, Xie Minghao obtained a bachelor’s degree in accounting from Shanghai Lixin University of Accounting and Finance, which merged with Shanghai Finance University. In May 2016, he further obtained a master’s degree in finance and organizational management from KEDGE Business School in France.

Related companies: Guotai Junan sh601211, Guotai